Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors-Reference-Cited by-同舟云学术

Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors

Published:2021-12 Issue:6 Volume:21 Page:e688-e692
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Werutsky Gustavo,Reinert Tomás,Rosa Mahira Lopes,Barrios Carlos Henrique

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Optimal management of hormone receptor positive metastatic breast cancer in 2016;Reinert;Ther Adv Med Oncol,2015

3. Real-world data: towards achieving the achievable in cancer care;Booth;Nat Rev Clin Oncol,2019

4. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012;Swallow;Curr Med Res Opin,2014

5. Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database;Burton;Curr Med Res Opin,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Tissue;The Journal of Molecular Diagnostics;2024-07

2. Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy;Breast Cancer Management;2023-06-01

3. Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence;Journal of Thrombosis and Haemostasis;2023-04

4. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer;Future Oncology;2023-03

5. Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies;Critical Reviews in Oncology/Hematology;2022-12